Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Bristol Myers Squibb

Sort by

Northwest Biotherapeutics, Bristol-Myers Squibb: Success for the Yervoy-Opdivo Combination in CHECKMATE-214 Trial Obviously is a Major Positive for BMY, but also has Important Implications for NWBO (NWBO, Buy, $0.19) (BMY, $60.80, Buy)

Thursday, September 7, 2017 · 9:56 am

Read More

Bristol-Myers Squibb: Disappointing Recent Press Release Causes Sharp Drop in Stock Price; I Remain at Buy (BMY, Buy, $49)

Tuesday, January 24, 2017 · 11:02 am

Read More

Bristol-Myers Squibb: Implications of Potentially Earlier than Expected Introduction of Keytruda Combined with Chemotherapy in the First Line Lung Cancer Setting (BMY, Buy, $56.31)

Thursday, January 12, 2017 · 11:52 am

Read More

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Tuesday, January 3, 2017 · 10:18 am

Read More

Immuno-Oncology is Probably The Most Explosive Commercial Opportunity in All of BioPharma; My Investment Picks are Bristol-Myers Squibb (BMY, Buy, $57.14) and Agenus (AGEN, Buy, $4.28))

Friday, December 9, 2016 · 2:37 pm

Read More

Bristol-Myers Squibb: Side Effect Issue with Hepatitis C Drug Creates a Buying Opportunity (BMY, $32.55)

Thursday, August 2, 2012 · 3:17 pm

Read More

Bristol-Myers Squibb: Best Positioned for Growth of the Four Big US Pharma Companies

Thursday, August 2, 2012 · 5:42 am

Read More

Bristol-Myers Squibb: Acquisition of Amylin is a Mild Posiitve (BMY, $35.89)

Monday, July 2, 2012 · 10:53 am

Read More

FDA Advisory Committee Recommendation for Approval of Xarelto Bodes Well for Approval of Eliquis (apixaban)

Friday, September 9, 2011 · 9:34 am

Read More

Xarelto's Problems are Eliquis' Opportunities (BMY. $29.90)

Thursday, September 8, 2011 · 8:27 am

Read More

New Product Potential is Outstanding But Patent Cliff is Looming (BMY, $29.28)

Thursday, July 28, 2011 · 1:43 pm

Read More

Eliquis Could Be A Blockbuster (BMY, $29.46)

Friday, July 22, 2011 · 10:58 am

Read More

Five Questions Posed by the FDA to Its Advisory Committee on Dapagliflozin (BMY, $28.96)

Friday, July 15, 2011 · 2:36 pm

Read More

Dapagliflozin's Date with the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (BMY, $29.17)

Thursday, July 14, 2011 · 9:30 am

Read More

Yervoy Was A Star at American Society of Oncology: Commercial Potential Is Enormous (BMY, $29.15)

Sunday, July 3, 2011 · 7:02 am

Read More

Ipilimumab's March 26 PDUFA Date Is Looming (BMY, $26.00)

Monday, May 9, 2011 · 3:12 pm

Read More

Ipilimumab's Approved Indications Exceed Expectations (BMY, $26.93)

Monday, May 9, 2011 · 2:41 pm

Read More

Initiating With Buy: Weighing an Excellent New Product Outlook Against the Pending Patent Cliff (BMY, $25

Monday, May 9, 2011 · 11:54 am

Read More

There are 18 reports on file.

« Back to Company Reports Index